Latest news with #Obesity
Medical News Today
3 days ago
- Health
- Medical News Today
Are lipedema and obesity related?
Lipedema and obesity both involve fat accumulation, but they are distinct conditions with different causes and treatment protocols. It is possible to have both conditions at the same time, but a person can have one without the other. Having obesity increases the risk of developing lipedema, but does not directly cause can be more challenging to diagnose if a person also has is a chronic (long term), progressive condition in which fat accumulates in the legs and feet. It typically affects people assigned female at birth more than those assigned male. Lipedema does not typically respond to weight loss methods, and treatments include wearing compression garments and undergoing lymphatic drainage is a complex, chronic condition in which fat accumulates throughout the body, not just in the lower extremities. Its causes may be metabolic, environmental, and genetic. Obesity typically improves with dietary and lifestyle changes. It can cause serious health complications, such as cardiovascular disease and type 2 table below summarizes the key differences between lipedema and it affectsmostly femalesmales and femalesPrevalence6.5% to 11% of US femalesone-third of US adultsFat distributionsymmetrical fat distribution in the hips, abdomen, and legs, that is 'nodular' or lumpythroughout the bodyPainpain, tenderness, and heaviness in the affected limbspossible pain caused by stress on the joints and inflammationCausesgenetic and hormonal factors—it may begin and worsen around puberty, pregnancy, and menopausemetabolic, environmental, and genetic factorsDiagnosismedical history, physical exam, no definitive testbody mass index (BMI) calculationTreatmentcompression garments, lymphatic drainage massage, specialized liposuction, pain management medicationsdiet and lifestyle changesImpact on daily lifephysical, psychological, and emotional physical, psychological, and emotional It can sometimes be difficult to distinguish between lipedema and obesity. A person concerned about fat accumulation in their lower body may suspect they have lipedema, particularly if traditional weight loss methods have not helped. Typically, lipedema fat does not affect the hands and feet. Lipedema fat stops abruptly at the ankle creating a cuff effect. A person with lipedema may also experience pain, tenderness, and easy is a good idea to discuss these symptoms with a doctor, who may ask about the person's family medical history and perform a physical exam. Diagnosing lipedema requires eliminating the possibility of other conditions, including obesity. The Lipedema Foundation provides a patient self-advocacy guide. It supports people who suspect they may have lipedema and those who have received a diagnosis to navigate their healthcare lipedema and obesity require different treatment approaches, people with either or both conditions can benefit from lifestyle measures, such as:eating a nutritious diet that does not provide more energy than the body needsgetting at least 150 minutes of moderate-intensity physical activity per weekavoiding long periods of inactivity»FIND CARE:Find a vascular specialist in your area today. Learn moreWhat causes heavy aching legs?Medicare and liposuction: What to knowHow much should I weigh for my height and age?What are the treatments for obesity?
Yahoo
7 days ago
- Health
- Yahoo
Study reveals primary cause of obesity — and it's not lack of exercise
Obesity among adults continues to be a major public health issue in the United States and other economically developed countries, according to the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO). "It's a mix of poor diet, high stress levels, lack of muscle and lack of frequent movement," Lindsay Allen, a registered dietitian nutritionist and owner of Back in Balance Nutrition in Florida, told Fox News Digital. While both overeating and lack of exercise are often to blame, a new global study suggests that one factor far outweighs the other. Your Dna Could Be Stopping You From Losing Weight, New Study Suggests Scientists studied more than 4,000 adults from 34 populations, ranging from hunter-gatherer communities to office workers. They analyzed each person's total energy expenditure (TEE), which is the number of calories burned daily, along with body fat percentage and BMI (body mass index). Read On The Fox News App When adjusted for body size, people across all lifestyles and income levels burned similar amounts of energy, even if their daily routines were drastically different. "The differences in body fat that we see across populations likely aren't due to major differences in activity level or total daily energy burned," study authors Amanda McGrosky (from Elon University in North Carolina) and Amy Luke (Loyola University in Illinois) told Fox News Digital. "Rather, excess body fat is likely primarily the product of too many 'calories in,' or eating more calories than are burned." Scientists May Have Discovered Why The Pounds Come Back After Losing Weight People in more economically developed areas burned more calories, the researchers noted — but that's primarily because they tend to weigh more, and heavier bodies naturally burn more energy. Published in the journal Proceedings of the National Academy of Sciences (PNAS), the study concluded that how much people eat plays a far greater role than the amount of exercise when it comes to putting on weight. "Our analyses suggest that increased energy intake has been roughly 10 times more important than declining activity rates in driving the modern obesity crisis," the authors stated. Dr. Brett Osborn, a Florida neurosurgeon and longevity expert, agrees with the adage that "you can't out-train a bad diet." "Exercise burns far fewer calories than people want to believe," Osborn, who was not involved in the study, told Fox News Digital. "This latest data only confirms what I've seen in my clinic: We're not gaining weight because we stopped moving. We're gaining because we're overfed." Allen pointed out that muscle mass should also be considered. "Having sufficient muscle is what drastically improves metabolism and fat-burning capabilities," she told Fox News Digital, also emphasizing the importance of stress levels. "People who live in high-stress societies tend to be fatter because stress hormones change our metabolism and shift us into 'survival mode.'" Scientists Can Detect Junk Food Consumption In Blood And Urine Tests Another finding involves ultraprocessed foods (UPFs), which have long ingredient lists that are often calorie-dense, shelf-stable and "highly palatable." "As more populations are exposed to increasing amounts of highly processed, highly palatable foods, we will likely see increases in obesity in regions with relatively low rates currently," the study authors predicted. Ultraprocessed foods tend to be easier to overeat due to their flavor and texture, and they also don't keep people feeling full, the study found. They are also more calorie-dense, meaning they pack more energy into smaller volumes, and are more easily absorbed, making it harder for the body to eliminate excess energy. "Ultraprocessed foods are engineered to override our biology, namely our satiety signaling in the brain," Osborn told Fox News Digital. "They also promote inflammation and shift our physiology to a state that favors fat accumulation over fat burning." The researchers pointed out that physical activity is still important, particularly for cardiovascular health, mental well-being and longevity. Allen noted that people "need to consider all the other benefits of exercise and shift the mindset away from how many calories they are burning (which actually doesn't work very well for weight loss) toward building as much strength and muscle as they can." Osborn agreed, recommending "progressively intense and challenging workouts" — strength training in particular — to help boost the metabolic rate and facilitate fat-burning. "As I always say to my patients, "By virtue of proper nutrition and strength training, your body will not only burn fat, but it will also burn fat fast." Click Here To Sign Up For Our Health Newsletter However, Allen noted, when it comes to preventing obesity, the findings point to excess calorie consumption — particularly ultraprocessed foods — as the major contributing factor. "If you're worried about excess body fat, focus on calories in," McGrosky and Luke advised. "Especially over the long term, it's much harder to meaningfully change the total number of calories you burn than it is to change the number of calories you take in." For more Health articles, visit Osborn added that the problem isn't laziness or lack of movement. "It's the constant stream of ultraprocessed, nutrient-void products being shoveled into mouths under the guise of health or convenience," he said. "And it's killing us — slowly, predictably and en masse."Original article source: Study reveals primary cause of obesity — and it's not lack of exercise Solve the daily Crossword
Fox News
18-07-2025
- Health
- Fox News
Study reveals primary cause of obesity — and it's not lack of exercise
Obesity among adults continues to be a major public health issue in the United States and other economically developed countries, according to the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO). "It's a mix of poor diet, high stress levels, lack of muscle and lack of frequent movement," Lindsay Allen, a registered dietitian nutritionist and owner of Back in Balance Nutrition in Florida, told Fox News Digital. While both overeating and lack of exercise are often to blame, a new global study suggests that one factor far outweighs the other. Scientists studied more than 4,000 adults from 34 populations, ranging from hunter-gatherer communities to office workers. They analyzed each person's total energy expenditure (TEE), which is the number of calories burned daily, along with body fat percentage and BMI (body mass index). When adjusted for body size, people across all lifestyles and income levels burned similar amounts of energy, even if their daily routines were drastically different. "The differences in body fat that we see across populations likely aren't due to major differences in activity level or total daily energy burned," study authors Amanda McGrosky (from Elon University in North Carolina) and Amy Luke (Loyola University in Illinois) told Fox News Digital. "Rather, excess body fat is likely primarily the product of too many 'calories in,' or eating more calories than are burned." People in more economically developed areas burned more calories, the researchers noted — but that's primarily because they tend to weigh more, and heavier bodies naturally burn more energy. Published in the journal Proceedings of the National Academy of Sciences (PNAS), the study concluded that how much people eat plays a far greater role than the amount of exercise when it comes to putting on weight. "Our analyses suggest that increased energy intake has been roughly 10 times more important than declining activity rates in driving the modern obesity crisis," the authors stated. Dr. Brett Osborn, a Florida neurosurgeon and longevity expert, agrees with the adage that "you can't out-train a bad diet." "Exercise burns far fewer calories than people want to believe," Osborn, who was not involved in the study, told Fox News Digital. "We're not gaining weight because we stopped moving. We're gaining because we're overfed." "This latest data only confirms what I've seen in my clinic: We're not gaining weight because we stopped moving. We're gaining because we're overfed." Allen pointed out that muscle mass should also be considered. "Having sufficient muscle is what drastically improves metabolism and fat-burning capabilities," she told Fox News Digital, also emphasizing the importance of stress levels. "People who live in high-stress societies tend to be fatter because stress hormones change our metabolism and shift us into 'survival mode.'" Another finding involves ultraprocessed foods (UPFs), which have long ingredient lists that are often calorie-dense, shelf-stable and "highly palatable." "As more populations are exposed to increasing amounts of highly processed, highly palatable foods, we will likely see increases in obesity in regions with relatively low rates currently," the study authors predicted. Ultraprocessed foods tend to be easier to overeat due to their flavor and texture, and they also don't keep people feeling full, the study found. They are also more calorie-dense, meaning they pack more energy into smaller volumes, and are more easily absorbed, making it harder for the body to eliminate excess energy. "Ultraprocessed foods are engineered to override our biology, namely our satiety signaling in the brain," Osborn told Fox News Digital. "They also promote inflammation and shift our physiology to a state that favors fat accumulation over fat burning." The researchers pointed out that physical activity is still important, particularly for cardiovascular health, mental well-being and longevity. Allen noted that people "need to consider all the other benefits of exercise and shift the mindset away from how many calories they are burning (which actually doesn't work very well for weight loss) toward building as much strength and muscle as they can." Osborn agreed, recommending "progressively intense and challenging workouts" — strength training in particular — to help boost the metabolic rate and facilitate fat-burning. "As I always say to my patients, "By virtue of proper nutrition and strength training, your body will not only burn fat, but it will also burn fat fast." However, Allen noted, when it comes to preventing obesity, the findings point to excess calorie consumption — particularly ultraprocessed foods — as the major contributing factor. "If you're worried about excess body fat, focus on calories in," McGrosky and Luke advised. "Especially over the long term, it's much harder to meaningfully change the total number of calories you burn than it is to change the number of calories you take in." Osborn added that the problem isn't laziness or lack of movement. "It's the constant stream of ultraprocessed, nutrient-void products being shoveled into mouths under the guise of health or convenience," he said. "And it's killing us — slowly, predictably and en masse."
CNA
18-07-2025
- Health
- CNA
What is behind the surge of obesity worldwide, and how is Singapore fighting back?
SINGAPORE: Obesity is not just a global problem, but one that is hitting Singapore hard. According to the latest Ministry of Health data from 2022, nearly 12 out of every 100 adults aged 18 to 74 in Singapore were obese - double the rate from 30 years ago. However, obesity is not a flaw or a simple lifestyle choice, but a complex, chronic disease that is often misunderstood and unfairly judged, according to healthcare experts. WHAT IS OBESITY? Dr Tham Kwang Wei, president of the Singapore Association for the Study of Obesity, noted a gradual rise in obesity prevalence in the population. 'Between 2010 and 2022 … we've hovered around anywhere from 10 plus per cent to currently 11.6 per cent … but I think if the measures had not been put in, we could have seen a larger rise,' said the Woodlands Health senior consultant. She noted these public health measures implemented by the government included public infrastructure that encourage physical activity as well as campaigns that encourage a healthier lifestyle and earlier health screenings. The World Health Organisation defines obesity as a Body Mass Index (BMI) of 30 or above. However, with regards to Singapore's population, Dr Tham said the health risks from obesity for Asians begin from a BMI of 27.5. Apart from looks or waistlines, doctors are also concerned about how obesity can lead to excess fat inside a person's body, causing health problems. 'When we have excess energy … that energy has to be stored somewhere … in the fat (cells). When the fat cells start to extend and are unable to tolerate more fat storage, then the fat needs to also flow somewhere else,' said Dr Tham. The excess fat could end up around a person's liver, heart or even in the muscles, she added. HEALTH RISKS FROM OBESITY Dr Tham noted that the fat surrounding vital organs can cause inflammatory responses and ill health. This can lead to an increased risk of heart disease, stroke, Type 2 diabetes, or fatty liver disease. Obesity is associated with more than 230 medical conditions, she added, with 77 per cent of patients with obesity seeking treatment at Woodlands Health hospital having at least three obesity-related complications (ORC) while 52 per cent have at least four such ORCs. Dr Tham said the most common ORC was musculoskeletal complaints, followed by obstructive sleep apnoea and metabolic-dysfunction associated steatotic liver disease, commonly known as fatty liver. She noted that many often do not view it as seriously as a chronic disease. 'They know it's serious, but they often seek help on their own. I don't think everybody needs to see a doctor, but they need to (see) obesity can lead to many serious, chronic diseases,' added Dr Tham. TREATMENT FOR OBESITY Lifestyle factors can lead to obesity, she said. These include stress, lack of physical activity and sleep issues like lack of adequate sleep or routines and environments that hinder proper restful sleep. Childhood obesity is another risk factor for adult obesity, added Dr Tham. She noted that children who enjoy processed, energy-dense food and snacks will have an increased risk of weight gain when they grow up, as they will consume such food as adults. The effects of obesity are not just medical but also deeply personal, affecting patients' daily lives, she said. 'Up to 80 per cent (of our patients) … are impacted by their weight, whether it's at home doing housework … at work or in public places,' said Dr Tham. While exercise and diet may help some in their weight loss journey, some may have their bodies working against them, she added. 'Energy regulation is disrupted by obesity. You may see that people say, 'I really don't eat much but I'm still putting on weight', and it's true in quite a number of people … (Their body's) metabolism has changed when they have obesity,' said Dr Tham. For those whose bodies are genetically rewired to store fat and resist weight loss, medical help is available, including ultra-low calorie diets, medication or metabolic and bariatric surgery options, according to experts. In tougher cases, patients may need help from a full medical team - a physician, dietitian, physiotherapist and psychologist. 'If a person with obesity has tried many, many times, it's really a signal for us to add on something beyond diet and lifestyle therapies … We may … introduce things like medications and even intensive diet, dietary interventions,' Dr Tham added. Surgery is another step for even more serious cases. Doctors may use shrink a patient's stomach through surgical procedures to make it smaller, or filling part of it using a gastric balloon so it holds less and induces a feeling of fullness in the patient. PREVENTION IS BETTER THAN CURE While treatments and therapies are available to manage obesity, national efforts to promote healthy living and fitness are being made to help people stay healthy and reduce weight gain before it starts. Dr Tham said the HealthierSG initiative has also helped to encourage people to visit their doctors and go for health screenings where they can do weight assessments. 'The environment is very, very important. And I think as a whole … our government has done a very good job,' she noted. 'We've seen a lot of infrastructure built around the environment, making healthcare very close to where we live, and making the environment very liveable,' she said, noting how people can easily access public exercise corners and fitness classes through ActiveSG.
Globe and Mail
16-07-2025
- Health
- Globe and Mail
Obesity Pipeline Appears Robust With 80+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's ' Obesity Pipeline Insigh t 2025 ' report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Othe besity pipeline landscape. It covers the Obesity pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Obesity therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Obesity pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Obesity Pipeline Report to explore emerging therapies, key Obesity Companies, and future Obesity treatment landscapes @ Obesity Pipeline Outlook Report Key Takeaways from the Obesity Pipeline Report In July 2025, Carmot Therapeutics Inc. announced a study to evaluate the efficacy and safety of CT-388 at low, middle, and high doses in participants who are overweight or obese with Type 2 diabetes mellitus (T2DM). In July 2025, Innovent Biologics (Suzhou) Co. Ltd. conducted a study is a multicenter, randomized, partially double-blind (double-blind in both the IBI362 group and the placebo group, with the tirbopeptide group open), placebo and active drug controlled design study. In July 2025, Zealand Pharma organized a study is to compare dose levels of petrelintide versus placebo with regards to effect on body weight, safety, and tolerability. Obesity is a chronic disease with a rapidly increasing prevalence associated with significant comorbidities. Petrelintide is a long-acting amylin analog in development for weight management. In July 2025, Eli Lilly and Company conducted a study is to determine if combining tirzepatide with mibavademab will result in more weight loss in adult participants than tirzepatide alone. The study will last about 74 weeks and may include up to 19 visits. In July 2025, Rhythm Pharmaceuticals Inc. organized a Phase 3 Multiple Independent Sub-studies of Setmelanotide in Patients With POMC/PCSK1, LEPR, NCOA1(SRC1), or SH2B1 Gene Variants in the Melanocortin-4 Receptor Pathway. DelveInsight's Obesity pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Obesity treatment. The leading Obesity Companies such as Zealand Pharma, Sciwind Biosciences, Genexine, Sirnaomics, Sparrow Pharmaceuticals, Shionogi, Regor Pharmaceuticals, Innovent Biologics, Pfizer, NodThera Limited, Boehringer Ingelheim, Fractyl Health, TransThera, Clearmind Medicine, PegBio, Biolingus, and others. Promising Obesity Therapies such as APHD-012, Bimagrumab, Semaglutide, CT-868, GLY-200, Bremelanotide, and others. Discover how the Obesity treatment paradigm is evolving. Access DelveInsight's in-depth Obesity Pipeline Analysis for a closer look at promising breakthroughs @ Obesity Clinical Trials and Studies Obesity Emerging Drugs Survodutide: Zealand Pharma Survodutide (BI 456906) is a long-acting glucagon/GLP-1 receptor dual agonist for once-weekly subcutaneous administration that activates two key gut hormone receptors simultaneously and may offer better efficacy than current single-hormone receptor agonist treatments. Survodutide is targeting the treatment of obesity and nonalcoholic steatohepatitis (NASH). Boehringer Ingelheim is advancing survodutide into three global Phase III trials in people living with overweight or obesity. Ecnoglutide: Sciwind Biosciences Glucagon-like peptide-1 (GLP-1) analogs are effective therapies in managing type 2 diabetes, obesity, and have demonstrated clinical potential as a treatment for NASH. Ecnoglutide (XW003) is a novel, cAMP signaling biased, long-acting GLP-1 analogue optimized for improved biological activity, cost-effective manufacturing, and once weekly dosing. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Obesity. CT-868: Carmot Therapeutics CT-868 is a dual GLP-1 and GIP receptor modulator with a unique pharmacological profile optimized for improved tolerability at the GLP-1 receptor. The combined action of GLP-1 and GIP results in greater body weight loss and glucose control. CT-868 is dosed once daily to maximize efficacy and tolerability. CT-868 dual agonist candidate was discovered using the chemotype evolution technology as a peptide-small molecule hybrid compound, able to mimic the native GLP-1 hormone. In the Phase I trial, CT-868 demonstrated compelling pharmacodynamic activity across several clinical measures in overweight and obese healthy individuals a safe and generally well-tolerated profile. Carmot Therapeutics is now expanding the observations in overweight and obese patients with type 2 diabetes to demonstrate CT-868's effects on glycemic control, weight loss, and tolerability. Currently, the drug is in the Phase II stage of development to treat obesity. DD01: D&D Pharmatech DD01 is a proprietary, imbalanced dual agonist of GLP-1 and glucagon receptors with a half-life of 11 days in non-human primates. DD01 is being developed as a potential disease-modifying agent for obesity and liver fatty disease. Treatment with DD01 caused weight loss, reduced liver fat, and improved glucose tolerance in preclinical obesity, diabetes, and fatty liver models. In preclinical models of diabetes and nonalcoholic fatty liver disease (NAFLD), DD01 could reduce weight and blood sugar and improve insulin sensitivity and lipid and fat metabolism, which could ameliorate NASH. DD01 demonstrated greater efficacy in preclinical models than semaglutide, an approved GLP-1R receptor agonist; from a mechanical perspective, the effect of DD01 persisted after cessation of treatment. It is currently being evaluated in Phase I clinical trial to investigate the safety, tolerability, PK, and PD of DD01 administered by subcutaneous (SC) injection in overweight/obese subjects with type 2 diabetes mellitus and nonalcoholic fatty liver disease (NAFLD). The Obesity pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Obesity with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Obesity Treatment. Obesity Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Obesity Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Obesity market. Get a detailed analysis of the latest innovations in the Obesity pipeline. Explore DelveInsight's expert-driven report today! @ Obesity Unmet Needs Obesity Companies Zealand Pharma, Sciwind Biosciences, Genexine, Sirnaomics, Sparrow Pharmaceuticals, Shionogi, Regor Pharmaceuticals, Innovent Biologics, Pfizer, NodThera Limited, Boehringer Ingelheim, Fractyl Health, TransThera, Clearmind Medicine, PegBio, Biolingus, and others. Obesity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Obesity Products have been categorized under various ROAs such as Oral Parenteral Intravenous Subcutaneous Topical Obesity Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Download DelveInsight's latest report to gain strategic insights into upcoming Obesity Therapies and key Obesity Developments @ Obesity Market Drivers and Barriers, and Future Perspectives Scope of the Obesity Pipeline Report Coverage- Global Obesity Companies- Zealand Pharma, Sciwind Biosciences, Genexine, Sirnaomics, Sparrow Pharmaceuticals, Shionogi, Regor Pharmaceuticals, Innovent Biologics, Pfizer, NodThera Limited, Boehringer Ingelheim, Fractyl Health, TransThera, Clearmind Medicine, PegBio, Biolingus, and others. Obesity Therapies- APHD-012, Bimagrumab, Semaglutide, CT-868, GLY-200, Bremelanotide, and others. Obesity Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Obesity Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Which companies are leading the race in Obesity drug development? Find out in DelveInsight's exclusive Obesity Pipeline Report—access it now! @ Obesity Emerging Drugs and Major Companies Table of Contents Introduction Executive Summary Obesity Overview Obesity Pipeline Therapeutics Obesity Therapeutic Assessment Late Stage Products (Phase III) Survodutide: Zealand Pharma Drug profiles in the detailed report….. Mid Stage Products (Phase II) CT-868: Carmot Therapeutics Drug profiles in the detailed report….. Early Stage Products (Phase I) DD01: D&D Pharmatech Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug name: Company name Drug profiles in the detailed report….. Inactive Obesity Products Obesity Key Companies Obesity Key Products Obesity Unmet Needs Obesity Market Drivers Obesity Market Barriers Obesity Future Perspectives and Conclusion Obesity Analyst Views Obesity Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
